You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
RadNet agreed to acquire OnRad for $350,000,000 in cash and 5,000,000 RadNet shares, plus an earn-out of up to $210,000,000 based on Post-Closing Annual Adjusted EBITDA for the fiscal year ending December 31, 2027; closing is expected in early 2027.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Earnings non-GAAP | $23.2M | Q2 2026 | — |
| Adjusted Earnings Per Share non-GAAP | $0.29 | Q2 2026 | — |
| Adjusted EBITDA - Digital Health Segment non-GAAP | $3.78M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA - Imaging Center non-GAAP | $97.18M | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA - Imaging Center Segment non-GAAP | $159.14M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA - Radnet, Inc. non-GAAP | $162.92M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA - Total Company non-GAAP | $99.66M | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) attributable to RadNet, Inc. common stockholders 7.53M
+6.36M Income taxes
+18.15M Interest expense
+660K Severance costs
+45.53M Depreciation and amortization
+10.54M Non-cash employee stock-based compensation
+1.12M Loss on sale and disposal of equipment and other
+0K Non-cash change in fair value of interest rate hedge
-3.96M Other income
+5.11M Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI
+1.31M Lease abandonment charges
+3.37M Loss (gain) on extinguishment of debt and related expenses
-3.16M Non-cash change to contingent consideration
+498K Non-operational rent expenses
+6.6M Acquisition transaction costs
= Adjusted EBITDA - Total Company 99.66M
|
|||
| Adjusted EBITDA Margin - Imaging Center Segment non-GAAP | 16.1% | Q2 2026 | — |
| advanced imaging as a percentage of total procedural volumes | 29.9% | Q2 2026 | — |
| aggregate advanced imaging procedural volumes growth | 21.2% | Q2 2026 | — |
| Annual Recurring Revenue (ARR) - Digital Health non-GAAP | $105.5M | Q2 2026 | — |
| balance sheet cash | $726.3M | Q2 2026 | — |
| CT volume growth | 20.9% | Q2 2026 | — |
| joint venture locations | 157 | Q2 2026 | — |
| new business Total Contract Value signed | $21M | Q2 2026 | — |
| owned and operated outpatient imaging centers | 442 | Q2 2026 | — |
| PET/CT volume growth | 31% | Q2 2026 | — |
| Procedures by Modality - CT | 352,734 | Second Quarter 2026 | — |
| Procedures by Modality - Mammography | 537,732 | Second Quarter 2026 | — |
| Procedures by Modality - MRI | 593,143 | Second Quarter 2026 | — |
| Procedures by Modality - Nuclear Medicine | 10,460 | Second Quarter 2026 | — |
| Procedures by Modality - PET/CT | 29,027 | Second Quarter 2026 | — |
| Procedures by Modality - Total | 3,262,013 | Second Quarter 2026 | — |
| Procedures by Modality - Ultrasound | 776,541 | Second Quarter 2026 | — |
| Procedures by Modality - X-ray and Other | 962,376 | Second Quarter 2026 | — |
| routine imaging volume growth | 7.9% | Q2 2026 | — |
| same-center advanced imaging procedural volumes growth | 9.6% | Q2 2026 | — |
| same-center CT volume growth | 8.6% | Q2 2026 | — |
| same-center MRI volume growth | 10.2% | Q2 2026 | — |
| same-center PET/CT volume growth | 8.8% | Q2 2026 | — |
| same-center routine imaging volume growth | 1.7% | Q2 2026 | — |
| Systemwide same center procedural volumes by modality - CT non-GAAP | 315,226 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - Mammography non-GAAP | 505,871 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - MR non-GAAP | 537,894 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - Nuclear Medicine non-GAAP | 8,442 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - PET/CT non-GAAP | 23,980 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - Total non-GAAP | 3,027,879 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - Ultrasound non-GAAP | 723,473 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - X-ray and Other non-GAAP | 912,993 | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RDNT
this stock
RadNet, Inc.
|
$6.27B | +9.3% | +13.0% | — | 11.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$250.82B | +16.8% | +14.5% | 35.7 | 1.3% |
|
DHR
Danaher Corp
|
$159.24B | -1.1% | +8.5% | 37.0 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.04B | -0.9% | +10.4% | 47.1 | 2.4% |
|
NTRA
Natera, Inc.
|
$52.75B | +58.8% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
RadNet agreed to acquire OnRad for $350,000,000 in cash and 5,000,000 RadNet shares, plus an earn-out of up to $210,000,000 based on Post-Closing Annual Adjusted EBITDA for the fiscal year ending December 31, 2027; closing is expected in early 2027.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RDNT | +5.9% | +14.4% | +48.9% | +6.2% | +9.3% |
| SPY | -4.7% | -5.3% | -0.8% | -3.0% | +7.5% |
| vs SPY | +10.7% | +19.7% | +49.7% | +9.2% | +1.8% |
